Gamifant ® (emapalumab-Iszg) is an interferon gamma (IFNγ)-blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic ...

Emapalumab is a monoclonal antibody that neutralises interferon gamma (IFN?), a key cytokine which contributes to the inflammation and tissue damage seen in MAS. The purpose of these two prospective ...

Results showed that MAS remission was seen in 13 of 14 patients with sHLH/MAS receiving emapalumab who had an inadequate response to high-dose glucocorticosteroidsWALTHAM, Mass., April 04, 2023 ...

STOCKHOLM, Sweden, Oct. 17, 2020 /PRNewswire/ -- Sobi™ today presented results from the sensitivity analysis from the pivotal phase 2/3 study (NCT01818492) of emapalumab in patients with primary HLH ...

Emapalumab is a monoclonal antibody that binds to and neutralises interferon gamma (IFNγ). In the US, emapalumab is indicated for the treatment of adult and paediatric (new-born and older) patients ...

Emapalumab is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Cytopenia. According to GlobalData, Phase II drugs for Cytopenia have a 63% phase transition success ...

Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's disease, including systemic juvenile ...

Gamifant ® (emapalumab-Iszg) is an interferon gamma (IFNγ)-blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic ...

STOCKHOLM, Sweden, Oct. 17, 2020 /PRNewswire/ -- Sobi™ today presented results from the sensitivity analysis from the pivotal phase 2/3 study (NCT01818492) of emapalumab in patients with primary HLH ...